Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease

Figure 1 Upregulation of KCa3. 1 expression in diseased livers. A: In rats subjected to biliary occlusion, hepatic KCa3.1 expression, probed with anti-KCa3.1 (SK4, IKCa1) antibody, was several-fold that in of sham operated rats. B: Densitometric analysis was made of Western blots for KCa3.1 expression in liver lysates from mice fed a standard diet or CDAHFD for 8 wk. Compared to its expression in livers from animals on a standard diet, KCa3.1 expression is increased several-fold in livers from the CDAHFD cohort (^aP < 0.05 vs standard diet). C: Left: Livers from rats administered TAA for 8 wk exhibited increased fibrosis evidenced by increased picrosirius red staining (^aP < 0.05 vs sham). D: Increased KCa3.1 expression significantly (^aP < 0.05 vs Sham) (middle). (20 ×), intense blue membranous staining (white arrow and right bottom) was noted in these fibrotic livers.